AssayIndex
Reports by quarter

Reports submitted in 2025-Q1 · page 13

Anomaly rule set expanded from seven rules to eleven. Median purity for the quarter is 99.14 % area, n=664. Read the 2025-Q1 state-of-the-index report →

672 records17 pagesmedian on this page 99.12 %updated 30 Jul 2026
ReportCompoundSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2025-020062P21SWBSWB-2408-T8372Janoshik2025-Q199.228.2890.7Buyer-sourced0PASS
AX-2025-020004RetatrutideSWBSWB-2411-R7167Nordanalyt2025-Q197.743.94104.5Buyer-sourced0PASS
AX-2025-019951TB-500HJHJ-2501-A6454Nordanalyt2025-Q199.414.80—Buyer-sourced1MARGINAL
AX-2025-019904TirzepatideHJHJ-2501-P5963Nordanalyt2025-Q198.572.82—Buyer-sourced0PASS
AX-2025-019660AfamelanotideTFCTFC-2502-Y2346Janoshik2025-Q199.444.4492.8Buyer-sourced1MARGINAL
AX-2025-019369GHRP-2HYBHYB-2501-R7240Janoshik2025-Q199.794.9598.6Buyer-sourced0PASS
AX-2025-019158LL-37SinoPepSNP-2411-X3762PeptideMeter2025-Q198.933.0393.9Buyer-sourced1MARGINAL
AX-2025-019157LL-37SinoPepSNP-2411-X3762Medutest2025-Q198.803.1594.8Buyer-sourced1MARGINAL
AX-2025-018962TirzepatideASYASY-{CAT}-1489Janoshik2025-Q199.006.6498.9Buyer-sourced0PASS
AX-2025-018951TirzepatideASYASY-{CAT}-1244Janoshik2025-Q198.474.81—Buyer-sourced0PASS
AX-2025-018433TirzepatideWWBWWB-2411-A2303Janoshik2025-Q198.761.91—Buyer-sourced0PASS
AX-2025-018411SemaglutideWWBWWB-2502-W1846VendorInvestigate2025-Q199.155.59—Buyer-sourced1MARGINAL
AX-2025-020989CJC-1295 with DACWXTWXT-2409-Y3760Kestrel2025-Q197.165.31—Buyer-sourced1FAIL
AX-2025-020790TB-500CPCCPC-2408-B9995Medutest2025-Q198.535.19—Buyer-sourced0PASS
AX-2025-020688SelankSGNSGN-2409-H8807Janoshik2025-Q198.386.17—Buyer-sourced0FAIL
AX-2025-020291BPC-157GGPepsGGPE-2502-S2559PeptideMeter2025-Q198.872.75—Buyer-sourced0PASS
AX-2025-019946AOD-9604HJHJ-2502-E7144Janoshik2025-Q198.591.90—Buyer-sourced0PASS
AX-2025-019810L-Glutathione (reduced)HomopeptideHOMO-2501-D4371Nordanalyt2025-Q199.939.0196.1Buyer-sourced1MARGINAL
AX-2025-019604GHRP-2TFCTFC-2411-A2083Janoshik2025-Q199.932.34—Supplier-supplied0PASS
AX-2025-019365TirzepatideHYBHYB-2408-R7015Janoshik2025-Q198.085.63100.2Buyer-sourced0PASS
AX-2025-019175Enclomiphene citrateSinoPepSNP-2412-F3914Janoshik2025-Q199.664.85105.1Buyer-sourced1FAIL
AX-2025-019156LL-37SinoPepSNP-2411-X3762Janoshik2025-Q199.402.5899.2Buyer-sourced1MARGINAL
AX-2025-018745CJC-1295 (no DAC)QSCQSC-2411-D7855PeptideMeter2025-Q198.794.06106.3Buyer-sourced0PASS
AX-2025-018542IpamorelinQYBQYB-2408-A4637PeptideMeter2025-Q199.934.5892.8Buyer-sourced0PASS
AX-2025-018477TirzepatideWWBWWB-2502-U2990Janoshik2025-Q198.873.59—Buyer-sourced1MARGINAL
AX-2025-020769SemaglutideSGNSGN-2410-D9265Kestrel2025-Q198.414.73—Buyer-sourced0PASS
AX-2025-019926TirzepatideHJHJ-2502-P6662VendorInvestigate2025-Q199.292.63104.7Buyer-sourced0PASS
AX-2025-019651GHRP-2TFCTFC-2502-D2333Medutest2025-Q199.725.0798.7Buyer-sourced0PASS
AX-2025-019368GHRP-2HYBHYB-2501-R7240Medutest2025-Q199.935.50105.5Buyer-sourced1MARGINAL
AX-2025-019139TesamorelinGSPGSP-2501-G3708Medutest2025-Q199.063.60—Supplier-supplied1MARGINAL
AX-2025-019065MK-677 (Ibutamoren mesylate)GSPGSP-2501-R2783Nordanalyt2025-Q199.266.13—Laboratory-retained0FAIL
AX-2025-018925CJC-1295 with DACTFSTFS-{CAT}-9795Medutest2025-Q199.082.79—Buyer-sourced2MARGINAL
AX-2025-018853DihexaFGPFGP-2408-S8496Kestrel2025-Q199.546.52—Buyer-sourced1FAIL
AX-2025-018789RetatrutideFGPFGP-2501-S8023VendorInvestigate2025-Q198.123.83—Laboratory-retained0PASS
AX-2025-018413SemaglutideWWBWWB-2502-W1846Kestrel2025-Q199.935.78105.7Buyer-sourced2FAIL
AX-2025-021128EpitalonSIGSIG-2412-6325VendorInvestigate2025-Q198.678.21—Buyer-sourced0FAIL
AX-2025-019120VilonGSPGSP-2411-J3700Kestrel2025-Q199.785.79101.2Buyer-sourced0FAIL
AX-2025-019057MK-677 (Ibutamoren mesylate)GSPGSP-2501-R2783Medutest2025-Q199.456.0796.3Buyer-sourced0FAIL
AX-2025-019001HexarelinASYASY-{CAT}-1786Nordanalyt2025-Q199.934.39—Buyer-sourced1MARGINAL
AX-2025-018467TirzepatideWWBWWB-2502-U2990Janoshik2025-Q199.623.56—Buyer-sourced1MARGINAL